featured
Dual Anti–CTLA-4 and Anti–PD-1 Blockade in High-Grade Neuroendocrine Neoplasms
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Basket Trial of Dual Anti– CTLA– 4 and Anti– PD– 1 Blockade in Rare Tumors (DART) SWOG S1609: High- Grade Neuroendocrine Neoplasm Cohort
Cancer 2021 Apr 21;[EPub Ahead of Print], SP Patel, E Mayerson, YK Chae, J Strosberg, J Wang, B Konda, J Hayward, CM McLeod, HX Chen, E Sharon, M Othus, CW Ryan, M Plets, CD Blanke, R KurzrockFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.